The EACH study assessed the efficacy of oxaliplatin , 5-fluorouracil , and leucovorin ( the FOLFOX4 regimen ) compared with doxorubicin alone in terms of overall survival ( OS ) , progression-free survival ( PFS ) , and safety in patients with advanced hepatocellular carcinoma ( HCC ) .